IP Library Granted Patent US 9,132,095
Granted Patent B2
US 9,132,095 · App. 14/064,685 · Granted Sep 15, 2015

Multiparticulate L-menthol formulations and related methods

Inventors: Syed Shah (Boca Raton, FL); Daniel Hassan (Boca Raton, FL); Sarah Hassan (Boca Raton, FL)
Assignee: Zx Pharma, LLC
A61K9/50A61K9/5026A61K9/5073A61K9/5089A61K31/045
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,132,095
App. No.
14/064,685
Granted
Sep 15, 2015
Kind
B2
Abstract

A multiparticulate formulation includes a plurality of individual spheroidal enteric coated cores containing L-menthol from an at least 80% pure L-menthol source. A subcoat is beneath the enteric coat. The enteric coated cores have a diameter of not more than 3 mm. The multiparticulate formulation may be used to treat gastrointestinal disorders, such as irritable bowel syndrome.

Claims (20)

1. A multiparticulate formulation comprising a plurality of individual spheroidal enteric coated cores having a diameter of not more than 3 mm, the enteric coated cores comprising solid crystalline L-menthol from an at least 80% pure L-menthol source and a subcoat beneath the enteric coat, wherein the enteric coated cores are combined in a capsule or packet-type pharmaceutical dosage form for oral delivery.

2. The multiparticulate formulation of claim 1 , wherein the enteric coated cores are effective to release at least 80% of the L-menthol within about 2 hours of being placed in an intestinal pH environment.

3. The multiparticulate formulation of claim 1 , wherein the cores further comprise a solubilizing agent effective for solubilizing L-menthol.

4. The multiparticulate formulation of claim 1 , wherein the cores further comprise an antioxidant effective for preventing the L-menthol from oxidizing.

5. The multiparticulate formulation of claim 4 , wherein the antioxidant is ascorbic acid.

6. The multiparticulate formulation of claim 1 , wherein the cores comprise about 30% to about 70% w/w L-menthol.

7. The multiparticulate formulation of claim 1 , wherein the enteric coated cores are effective to release no more than about 10% of the L-menthol within about 2 hours of being placed in a 0.1 N HCl solution and, subsequently, no less than about 85% of the L-menthol within about two hours of being placed in a substantially neutral pH environment.

8. The multiparticulate formulation of claim 1 , wherein, in the enteric coated cores, the enteric coat is positioned over the subcoat and the subcoat is positioned over the core.

9. A method of making a multiparticulate formulation, the method comprising:

preparing a plurality of individual spheroidal cores by blending solid crystalline L-menthol from an at least 80% pure L-menthol source with one or more excipients;

applying a subcoat to the cores to form subcoated cores;

enteric coating the subcoated cores to form enteric coated cores; and

drying the enteric coated cores to form dried enteric coated cores having a diameter of not more than 3 mm.

10. The method of claim 9 , wherein the dried enteric coated cores are effective to release at least 80% of the L-menthol within about 2 hours of being placed in an intestinal pH environment.

11. The method of claim 9 , further comprising mixing an L-menthol solubilizing agent with the L-menthol when preparing the cores.

12. A method of treating a gastrointestinal disorder in a subject, the method comprising administering to the subject a multiparticulate composition comprising a plurality of individual spheroidal enteric coated cores having a diameter of not more than 3 mm, the enteric coated cores comprising solid crystalline L-menthol from an at least 80% pure L-menthol source and a subcoat beneath the enteric coat.

13. The method of claim 12 , wherein the gastrointestinal disorder is irritable bowel syndrome.

14. The method of claim 12 , wherein the enteric coated cores are effective to release at least 80% of the L-menthol within about 2 hours of being placed in an intestinal pH environment.

15. The method of claim 12 , wherein the cores further comprise a solubilizing agent effective for solubilizing L-menthol.

16. The multiparticulate formulation of claim 1 , wherein the solid crystalline L-menthol is micronized.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2020
From: ZX PHARMA, LLC
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054516/0078 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2014
From: SHAH, SYED M.; HASSAN, SARAH; HASSAN, DANIEL
To: ZX PHARMA, LLC
Reel/Frame 032775/0262 →
Continuity (4)
Continuation 13367747 · Feb 7, 2012
Provisional Application 61441716 · Feb 11, 2011
Provisional Application 61486523 · May 16, 2011
Related Publication 20140065230A1 · Mar 6, 2014